ADC Therapeutics (ADCT) Cost of Revenue (2020 - 2023)
Historic Cost of Revenue for ADC Therapeutics (ADCT) over the last 4 years, with Q3 2023 value amounting to $13.7 million.
- ADC Therapeutics' Cost of Revenue rose 96023.17% to $13.7 million in Q3 2023 from the same period last year, while for Sep 2023 it was $517.8 million, marking a year-over-year increase of 1255717.7%. This contributed to the annual value of $4.6 billion for FY2022, which is 33149851.08% up from last year.
- Per ADC Therapeutics' latest filing, its Cost of Revenue stood at $13.7 million for Q3 2023, which was up 96023.17% from $14.5 million recorded in Q2 2023.
- In the past 5 years, ADC Therapeutics' Cost of Revenue registered a high of $489.0 million during Q4 2022, and its lowest value of $770.0 during Q4 2021.
- Over the past 4 years, ADC Therapeutics' median Cost of Revenue value was $1.8 million (recorded in 2022), while the average stood at $44.9 million.
- Within the past 5 years, the most significant YoY rise in ADC Therapeutics' Cost of Revenue was 6350639350.65% (2022), while the steepest drop was 9619.73% (2022).
- ADC Therapeutics' Cost of Revenue (Quarter) stood at $2.6 million in 2020, then tumbled by 99.97% to $770.0 in 2021, then soared by 63506393.51% to $489.0 million in 2022, then plummeted by 97.19% to $13.7 million in 2023.
- Its Cost of Revenue was $13.7 million in Q3 2023, compared to $14.5 million in Q2 2023 and $590000.0 in Q1 2023.